Bevacizumab in the treatment of colorectal cancer

Bibliography

• JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57:43-66.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353-364.
   PubMed Web of Science ®Google Scholar
• JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7:987-989.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669-676.
   PubMed Web of Science ®Google Scholar
• GERBER HP, FERRARA N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. (2005) 65:671-680.
   PubMed Web of Science ®Google Scholar
• CARMELIET P, FERREIRA V, BREIER G et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380:435-439.
   PubMed Web of Science ®Google Scholar
• ISHIGAMI SI, ARII S, FURUTANI M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer (1998) 78:1379-1384.
   PubMed Web of Science ®Google Scholar
• HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005) 23:1011-1027.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, ANAISSIE E, STOPECK A et al.: Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin. Cancer Res. (2004) 10:88-95.
   PubMed Web of Science ®Google Scholar
• EICHHORN ME, STRIETH S, DELLIAN M: Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist. Updat. (2004) 7:125-138.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356:115-124.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VAN OOSTEROM AT, GARRETT CR et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 368:1329-1338.
   PubMed Web of Science ®Google Scholar
• BATES D: ZD-6474. AstraZeneca. Curr. Opin. Investig. Drugs (2003) 4:1468-1472.
   PubMedGoogle Scholar
• BERGSLAND EK: Update on clinical trials targeting vascular endothelial growth factor in cancer. Am. J. Health Syst. Pharm. (2004) 61:S12-S20.
   PubMed Web of Science ®Google Scholar
• TYAGI P: Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin. Colorectal Cancer (2005) 5:24-26.
   PubMedGoogle Scholar
• KONNER J, DUPONT J: Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin. Colorectal Cancer (2004) 4(Suppl. 2):S81-S85.
   PubMedGoogle Scholar
• KIM KJ, LI B, HOUCK K, WINER J, FERRARA N: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors (1992) 7:53-64.
   PubMedGoogle Scholar
• KRAMER I, LIPP HP: Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J. Clin. Pharm. Ther. (2007) 32:1-14.
   Google Scholar
• KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95:1789-1797.
   PubMed Web of Science ®Google Scholar
• WILDIERS H, GUETENS G, DE BOECK G et al.: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer (2003) 88:1979-1986.
   PubMed Web of Science ®Google Scholar
• WILLETT CG, BOUCHER Y, DI TOMASO E et al.: Direct Evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10:145-147.
   PubMed Web of Science ®Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
   PubMed Web of Science ®Google Scholar
• KABBINAVAR F, ZURLO A, IRL C, HURWITZ H: Bevacizumab improves outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) independent of baseline risk. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2006) 24(18S):3539.
   Google Scholar
• KABBINAVAR FF, HAMBLETON J, MASS RD, HURWITZ HI, BERGSLAND E, SARKAR S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. (2005) 23:3706-3712.
   PubMed Web of Science ®Google Scholar
• GIANTONIO BJ: Bevacizumab (anti-VEGF) plusIFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA (22 – 24 January 2004).
   Google Scholar
• FUCHS C, MARSHALL J, MITCHELL E et al.: A randomized trial of first-line irinotecan/fluoropryimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2006) 24:3506.
   Google Scholar
• GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:4-6.
   PubMed Web of Science ®Google Scholar
• HOCHSTER H: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2006) 24:3510.
   Web of Science ®Google Scholar
• SALTZ LB, CLARKE S, DIAZ RUBIO E et al.: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA (19 – 21 January 2007) Abstract 238.
   Google Scholar
• CASSIDY J, CLARKE S, DIAZ RUBIO E et al.: XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA (19 – 21 January 2007) Abstract 270.
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. (2007) 25(12):(In Press).
   Google Scholar
• GIANTONIO BJ, CATALANO PJ, O’DWYER PJ, MEROPOL NJ, BENSON AB: Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group’s Study E3200. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2006) 24(18S):3538.
   Google Scholar
• CHEN HX, MOONEY M, BORON M et al.: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J. Clin. Oncol. (2006) 24:3354-3360.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SALVATORE S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, LENZ H, KINDLER H et al.: Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL, USA (27 – 29 January 2005) Abstract 169b.
   Google Scholar
• PANDE A: Bevacizumab (BV) induced hypertension (HT): a manageable toxicity. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2006) 24:242s.
   Google Scholar
• HEDRICK E, KOZLOFF M, HAINSWORTH J et al.: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2006) 24(18S):155s (Abstract 3536).
   Google Scholar
• KOZLOFF M, HAINSWORTH J, BADARINATH S: Survival of patients (pts) with mCRC treated with bevacizumab in combination with chemotherapy: results from the BRiTE registry. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA (19 – 21 January 2007) Abstract 364.
   Google Scholar
• SUGIMOTO H, HAMANO Y, CHARYTAN D et al.: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. (2003) 278:12605-12608.
   PubMed Web of Science ®Google Scholar
• HAMBLETON J: Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):3528.
   Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184-2191.
   PubMed Web of Science ®Google Scholar
• SKILLINGS J: Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J. Clin. Oncol. ASCO Annual Meeting Proceedings (2005) 23(16S):3019.
   Web of Science ®Google Scholar
• SCAPPATICCI F, FEHRENBACHER L, CARTWRIGHT T et al.: Lack of effect of bevacizumab on wound healing/bleeding complications when given 28 – 60 days following primary cancer surgery. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):3530.
   Google Scholar
• KESMODEL SB, ELLIS LM, CHANG GJ et al.: Complication rates following hepatic surgery in patients recieving neoadjuvant bevacizumab for colorectal cancer liver metastases. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA (19 – 21 January 2007) Abstract 234.
   Google Scholar
• GLUSKER P, RECHT L, LANE B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. (2006) 354:980-982; discussion 980-982.
   PubMed Web of Science ®Google Scholar
• MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. (2001) 19:851-856.
   PubMed Web of Science ®Google Scholar
• BORGSTROM P, GOLD DP, HILLAN KJ, FERRARA N: Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. (1999) 19(5B):4203-4214.
   PubMed Web of Science ®Google Scholar
• PREWETT M, HUBER J, LI Y et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59(20):5209-5218.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, LIU W, DAVIS DW et al.: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer (2000) 89(3):488-499.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. (2000) 15(1):29-41.
   PubMedGoogle Scholar
• GRIFFIN RJ, WILLIAMS BW, WILD R, CHERRINGTON JM, PARK H, SONG CW: Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. (2002) 62(6):1702-1706.
   PubMed Web of Science ®Google Scholar